9-me-bc

9-Me-BC (9-Methyl-β-carboline) is a nootropic compound with neuroprotective and cognitive-enhancing properties. It is known to promote dopaminergic neuron health by upregulating dopamine synthesis and reducing oxidative stress. Additionally, 9-Me-BC has been shown to support synaptogenesis and neuroplasticity, contributing to improved memory, focus, motivation, and overall cognitive function. Studies suggest that it may also have anti-inflammatory effects in the brain, potentially aiding in long-term cognitive health and protection against neurodegenerative diseases.

For a comprehensive description and detailed lab analysis, please refer to the sections below.

From 49.90

Quantity (grams)

Secure and trusted checkout with

9-Me-BC  Powder

9-Me-BC (9-Methyl-β-carboline) is a synthetic derivative of β-carboline, a class of compounds known for their interaction with various neurotransmitter systems. 9-Me-BC as a nootropic has attracted significant interest due to its neuroprotective, neurotrophic, and cognitive-enhancing effects, particularly within the dopaminergic system. This compound is characterized by a methyl group attached to the 9-position of the β-carboline ring, which enhances its ability to influence dopaminergic neurons.

Mechanism of Action:

9-Me-BC acts primarily on dopaminergic neurons by increasing the synthesis of dopamine, a neurotransmitter critical for motivation, reward, mood regulation, and cognitive function. It achieves this by upregulating tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis. A key study by Polanski et al. (2010) found that 9-Me-BC significantly increased TH expression in cultured dopaminergic neurons, thereby boosting dopamine production and availability.

Additionally, 9-Me-BC influences the dopamine transporter (DAT), responsible for the reuptake of dopamine from the synaptic cleft. By modulating DAT, it extends dopamine’s activity in the brain, leading to enhanced dopaminergic signaling. This can improve motivation, attention, and mood, as reported in Seifert et al. (2013), where 9-Me-BC administration increased synaptic plasticity in rodent models, supporting its role in memory and learning enhancement.

Neuroprotective Properties:

9-Me-BC has demonstrated strong neuroprotective effects by reducing oxidative stress and neuroinflammation, which are key contributors to neurodegenerative diseases. In a study by Liu et al. (2012), 9-Me-BC was found to lower levels of reactive oxygen species (ROS) in dopaminergic neurons, protecting them from oxidative damage and preventing mitochondrial dysfunction. The compound also reduced the expression of pro-inflammatory cytokines like TNF-α and IL-6, which are commonly elevated in conditions such as Alzheimer’s and Parkinson’s disease.

Moreover, 9-Me-BC promotes the survival of neurons by enhancing the expression of brain-derived neurotrophic factor (BDNF), which plays a key role in synaptogenesis and neuroplasticity. This neurotrophic action was observed in research by Heil et al. (2015), where 9-Me-B.C facilitated synaptic growth and neuron survival in in vitro models, highlighting its potential in slowing the progression of neurodegenerative diseases.

Cognitive Benefits:

  • Memory and Learning: In a controlled animal study by Polanski et al. (2011), 9-Me-BC administration improved long-term memory retention and learning ability. The study noted enhanced synaptic plasticity and increased neurogenesis in the hippocampus, the brain region associated with memory formation.
  • Focus and Attention: Due to its dopaminergic activity, 9-Me-B.C improves attention span and mental clarity. Seifert et al. (2013) also reported that the compound could reverse cognitive decline in models of aging, improving performance in complex cognitive tasks.
  • Mood and Motivation: 9-Me-BC has been noted for its potential to elevate mood and reduce fatigue. In a behavioral study, animals treated with 9-Me-BC displayed increased motivation and exploration behavior, consistent with dopamine’s role in reward and pleasure.

Additional Effects and limitation:

  • Recent findings suggest that 9-ME-BC may undergo hepatic metabolism into 2,9-dimethyl-β-carboline, a structurally related β-carboline with potential neurotoxic effects.

    Due to its high lipophilicity, this class of compounds is known to accumulate in brain tissue, where it may persist for extended periods, potentially leading to dopaminergic dysregulation or oxidative stress.

    Reported effects in non-clinical environments include symptoms resembling dopamine overstimulation, followed by neurochemical rebound effects (anhedonia, fatigue, motor instability).

  • Anti-inflammatory: 9-Me-B.C has demonstrated significant anti-inflammatory effects, which may help reduce neuroinflammation in degenerative conditions. In a study conducted by Ziegler et al. (2014), 9-Me-B.C reduced inflammation-induced damage in glial cells, preventing the overproduction of pro-inflammatory cytokines.
  • Protection Against Neurotoxins: 9-Me-BC has shown promise in protecting dopaminergic neurons from neurotoxic substances like MPP+, a known inducer of Parkinson-like symptoms. In an in vitro study by Polanski et al. (2010), 9-Me-B.C mitigated MPP+-induced neuronal death, suggesting its potential in therapeutic interventions for Parkinson’s disease.

Also, 9-Me-B.C, identified as an inhibitor of both monoamine oxidase A and monoamine oxidase B, has been suggested for further exploration in the context of Parkinson’s disease treatment.

For a full lab analysis, including purity testing, molecular structure, and pharmacological profiles, please refer to the next tabs.

Show More

Description

9-Me-BC  Powder

9-Me-BC (9-Methyl-β-carboline) is a synthetic derivative of β-carboline, a class of compounds known for their interaction with various neurotransmitter systems. 9-Me-BC as a nootropic has attracted significant interest due to its neuroprotective, neurotrophic, and cognitive-enhancing effects, particularly within the dopaminergic system. This compound is characterized by a methyl group attached to the 9-position of the β-carboline ring, which enhances its ability to influence dopaminergic neurons.

Mechanism of Action:

9-Me-BC acts primarily on dopaminergic neurons by increasing the synthesis of dopamine, a neurotransmitter critical for motivation, reward, mood regulation, and cognitive function. It achieves this by upregulating tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis. A key study by Polanski et al. (2010) found that 9-Me-BC significantly increased TH expression in cultured dopaminergic neurons, thereby boosting dopamine production and availability.

Additionally, 9-Me-BC influences the dopamine transporter (DAT), responsible for the reuptake of dopamine from the synaptic cleft. By modulating DAT, it extends dopamine’s activity in the brain, leading to enhanced dopaminergic signaling. This can improve motivation, attention, and mood, as reported in Seifert et al. (2013), where 9-Me-BC administration increased synaptic plasticity in rodent models, supporting its role in memory and learning enhancement.

Neuroprotective Properties:

9-Me-BC has demonstrated strong neuroprotective effects by reducing oxidative stress and neuroinflammation, which are key contributors to neurodegenerative diseases. In a study by Liu et al. (2012), 9-Me-BC was found to lower levels of reactive oxygen species (ROS) in dopaminergic neurons, protecting them from oxidative damage and preventing mitochondrial dysfunction. The compound also reduced the expression of pro-inflammatory cytokines like TNF-α and IL-6, which are commonly elevated in conditions such as Alzheimer’s and Parkinson’s disease.

Moreover, 9-Me-BC promotes the survival of neurons by enhancing the expression of brain-derived neurotrophic factor (BDNF), which plays a key role in synaptogenesis and neuroplasticity. This neurotrophic action was observed in research by Heil et al. (2015), where 9-Me-B.C facilitated synaptic growth and neuron survival in in vitro models, highlighting its potential in slowing the progression of neurodegenerative diseases.

Cognitive Benefits:

  • Memory and Learning: In a controlled animal study by Polanski et al. (2011), 9-Me-BC administration improved long-term memory retention and learning ability. The study noted enhanced synaptic plasticity and increased neurogenesis in the hippocampus, the brain region associated with memory formation.
  • Focus and Attention: Due to its dopaminergic activity, 9-Me-B.C improves attention span and mental clarity. Seifert et al. (2013) also reported that the compound could reverse cognitive decline in models of aging, improving performance in complex cognitive tasks.
  • Mood and Motivation: 9-Me-BC has been noted for its potential to elevate mood and reduce fatigue. In a behavioral study, animals treated with 9-Me-BC displayed increased motivation and exploration behavior, consistent with dopamine’s role in reward and pleasure.

Additional Effects and limitation:

  • Recent findings suggest that 9-ME-BC may undergo hepatic metabolism into 2,9-dimethyl-β-carboline, a structurally related β-carboline with potential neurotoxic effects.

    Due to its high lipophilicity, this class of compounds is known to accumulate in brain tissue, where it may persist for extended periods, potentially leading to dopaminergic dysregulation or oxidative stress.

    Reported effects in non-clinical environments include symptoms resembling dopamine overstimulation, followed by neurochemical rebound effects (anhedonia, fatigue, motor instability).

  • Anti-inflammatory: 9-Me-B.C has demonstrated significant anti-inflammatory effects, which may help reduce neuroinflammation in degenerative conditions. In a study conducted by Ziegler et al. (2014), 9-Me-B.C reduced inflammation-induced damage in glial cells, preventing the overproduction of pro-inflammatory cytokines.
  • Protection Against Neurotoxins: 9-Me-BC has shown promise in protecting dopaminergic neurons from neurotoxic substances like MPP+, a known inducer of Parkinson-like symptoms. In an in vitro study by Polanski et al. (2010), 9-Me-B.C mitigated MPP+-induced neuronal death, suggesting its potential in therapeutic interventions for Parkinson’s disease.

Also, 9-Me-B.C, identified as an inhibitor of both monoamine oxidase A and monoamine oxidase B, has been suggested for further exploration in the context of Parkinson’s disease treatment.

For a full lab analysis, including purity testing, molecular structure, and pharmacological profiles, please refer to the next tabs.

Lab Analysis


Product PDF Preview

View full report

COA_9-Me-BC_2024-03-05

2303EURO.741F_9 ME BC LOT= 230423 (HNMR)

2302EURO.193C_9 ME BC Lot=180323 (HNMR)

2302EURO.746C_9 ME BC LOT= 180323 (HNMR)

 

Chemical Informations

Technical Information
CAS Number 2521-07-5
Molar Mass 182.27 g/mol
Chemical Formula C₁₂H₁₀N₂
IUPAC Name 9-Methylpyrido[3,4-b]indole
Synonyms 9-Methyl-β-carboline, 9-Methyl-9H-β-carboline, 9-Methylnorharman,
9-methyl-beta-carboline, 9-methyl-|A-carboline,
9-methylpyrido[3,4-b]indole, 9-Me-BC/9-methyl-9H-pyrido[3,4-b]indoleM2818
Application MOA-A, MOA-B Inhibitor
Appearance Tan powder
Physical State Solid
Purity ≥98%
Solubility – Soluble in DMSO
Storage Conditions Store at room temperature, tightly sealed, away from heat, light, and moisture.

Our Products

Related Products